GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $73 billion and impressive gross margins of 72%, announced today that the China National Medical (TASE ...

GSK (GSK) announced that the China National Medical Products Administration, CNMPA, has accepted for review the new drug application for the ...

GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...

While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

China NMPA accepts for review GSK’s Nucala NDA to treat patients with chronic obstructive pulmonary disease: London, UK Friday, February 21, 2025, 09:00 Hrs [IST] GSK plc announ ...

GSK PLC on Thursday said its monoclonal antibody Nucala, also known as mepolizumab, has been accepted for review in China. The London-based pharmaceutical company said the China Medical Products ...

Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...

A: Emma Walmsley, CEO, mentioned that while there are short-term pressures acknowledged for 2024 and 2025, GSK remains ambitious about the long-term potential in China. The partnership with Joffe ...

GSK’s vaccine sales in China reflect broader pressures facing multinational pharma firms in the Chinese market. In December 2024, GSK’s Chinese distribution deal for Shingrix with Chongqing ...

GSK (GSK) announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, Labour and ...

A roundup of recent health news highlights policy changes affecting FDA language use, drug industry meetings with President ...